Lobaplatin: Difference between revisions
CSV import |
CSV import Tags: mobile edit mobile web edit |
||
| Line 1: | Line 1: | ||
{{Short description|Overview of the chemotherapy drug Lobaplatin}} | |||
{{Drugbox | |||
| verifiedfields = changed | |||
| verifiedrevid = 477002123 | |||
| image = Lobaplatin.svg | |||
| image_size = 200px | |||
| image_alt = Chemical structure of Lobaplatin | |||
}} | |||
'''Lobaplatin''' is a [[platinum-based antineoplastic agent]] used in the treatment of various types of [[cancer]]. It is a third-generation platinum compound, following [[cisplatin]] and [[carboplatin]], and is known for its improved safety profile and efficacy. | |||
Lobaplatin is a platinum | |||
==Chemical Structure== | |||
[[File:Lobaplatin.svg|thumb|right|Chemical structure of Lobaplatin]] | |||
Lobaplatin is a complex of platinum with a cyclobutane dicarboxylate ligand and a 1,2-diaminocyclohexane carrier ligand. This structure allows it to form cross-links with [[DNA]], inhibiting DNA replication and transcription, which ultimately leads to cell death. | |||
==Mechanism of Action== | ==Mechanism of Action== | ||
Lobaplatin | Lobaplatin exerts its antitumor effects by binding to [[DNA]] and forming intrastrand cross-links between adjacent guanine bases. This cross-linking disrupts the DNA double helix, preventing [[DNA replication]] and [[transcription]], and triggering [[apoptosis]] in rapidly dividing cancer cells. | ||
==Clinical | ==Clinical Uses== | ||
Lobaplatin is used in the treatment of | Lobaplatin is primarily used in the treatment of [[breast cancer]], [[ovarian cancer]], and [[small cell lung cancer]]. It is often administered in combination with other chemotherapeutic agents to enhance its efficacy. | ||
==Side Effects== | ==Side Effects== | ||
Common side effects of Lobaplatin include [[myelosuppression]], [[nausea]], and [[vomiting]]. It is generally better tolerated than earlier platinum-based drugs, with a lower incidence of [[nephrotoxicity]] and [[neurotoxicity]]. | |||
==Pharmacokinetics== | |||
Lobaplatin is administered intravenously and exhibits a biphasic elimination pattern. It is primarily excreted through the [[kidneys]], and dose adjustments may be necessary in patients with renal impairment. | |||
== | ==Development and Approval== | ||
Lobaplatin was developed to overcome the limitations of earlier platinum drugs, such as [[cisplatin]] and [[carboplatin]]. It has been approved for use in several countries, although its availability may vary. | |||
== | ==Related pages== | ||
* [[ | * [[Cisplatin]] | ||
* [[Carboplatin]] | |||
* [[Oxaliplatin]] | |||
* [[Chemotherapy]] | * [[Chemotherapy]] | ||
* [[ | * [[Antineoplastic agents]] | ||
[[Category: | [[Category:Platinum-based antineoplastic agents]] | ||
[[Category: | [[Category:Chemotherapy]] | ||
Latest revision as of 03:41, 13 February 2025
Overview of the chemotherapy drug Lobaplatin
| Lobaplatin | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Lobaplatin is a platinum-based antineoplastic agent used in the treatment of various types of cancer. It is a third-generation platinum compound, following cisplatin and carboplatin, and is known for its improved safety profile and efficacy.
Chemical Structure[edit]
Lobaplatin is a complex of platinum with a cyclobutane dicarboxylate ligand and a 1,2-diaminocyclohexane carrier ligand. This structure allows it to form cross-links with DNA, inhibiting DNA replication and transcription, which ultimately leads to cell death.
Mechanism of Action[edit]
Lobaplatin exerts its antitumor effects by binding to DNA and forming intrastrand cross-links between adjacent guanine bases. This cross-linking disrupts the DNA double helix, preventing DNA replication and transcription, and triggering apoptosis in rapidly dividing cancer cells.
Clinical Uses[edit]
Lobaplatin is primarily used in the treatment of breast cancer, ovarian cancer, and small cell lung cancer. It is often administered in combination with other chemotherapeutic agents to enhance its efficacy.
Side Effects[edit]
Common side effects of Lobaplatin include myelosuppression, nausea, and vomiting. It is generally better tolerated than earlier platinum-based drugs, with a lower incidence of nephrotoxicity and neurotoxicity.
Pharmacokinetics[edit]
Lobaplatin is administered intravenously and exhibits a biphasic elimination pattern. It is primarily excreted through the kidneys, and dose adjustments may be necessary in patients with renal impairment.
Development and Approval[edit]
Lobaplatin was developed to overcome the limitations of earlier platinum drugs, such as cisplatin and carboplatin. It has been approved for use in several countries, although its availability may vary.
